论文部分内容阅读
目的探讨PTEN、CyclinD1蛋白在宫颈鳞癌组织中的表达及临床意义。方法对我院45例宫颈鳞癌患者及45例健康体检患者,分别检测PTEN和CyclinD1蛋白,并对其结果进行分析总结。结果我院45例宫颈鳞癌患者PTEN阳性13例占28.9%、阴性32例占71.1%,45例健康体检患者PTEN阳性43例占95.6%、阴性2例占4.4%;45例宫颈鳞癌患者CyclinD1阳性29例占64.4%、阴性16例占35.6%,45例健康体检患者CyclinD1阳性0例、阴性45例占100%。在宫颈鳞癌组织CyclinD1的阳性表达率与组织学分级有关,低分化期阳性率明显高于高中分化期。与临床分期也有关,临床Ⅲ期表达率明显高于Ⅰ期～Ⅱ期。PTEN的阳性表达率随组织学分级的增加而下降,低分化期阳性率明显低于高中分化期,随临床期别的增高而降低,临床Ⅲ期表达率明显低于Ⅰ期～Ⅱ期。结论 PTEN和CyclinD1蛋白可作为临床诊断宫颈鳞癌的发展,早期诊断和科学评价肿瘤预后、指导临床治疗的生物学观察指标。
Objective To investigate the expression of PTEN and CyclinD1 in cervical squamous cell carcinoma and its clinical significance. Methods 45 patients with cervical squamous cell carcinoma in our hospital and 45 healthy patients were examined for PTEN and CyclinD1 protein, and the results were analyzed and summarized. Results 45 cases of cervical squamous cell carcinoma in our hospital were positive for PTEN 13 cases accounted for 28.9%, negative 32 cases accounted for 71.1%, 45 cases of healthy people PTEN positive 43 cases accounted for 95.6%, negative 2 cases accounted for 4.4%; 45 cases of cervical squamous cell carcinoma CyclinD1 positive 29 cases accounted for 64.4%, negative 16 cases accounted for 35.6%, 45 cases of health examination patients CyclinD1 positive 0 cases, negative 45 cases accounted for 100%. The positive expression rate of CyclinD1 in cervical squamous cell carcinoma was related to the histological grade, the positive rate in poorly differentiated phase was significantly higher than that in high-school differentiation. And clinical stage is also related to the clinical stage Ⅲ expression was significantly higher than Ⅰ ~ Ⅱ. The positive rate of PTEN decreased with the increase of histological grade, the positive rate of low differentiation was significantly lower than that of high school differentiation, and decreased with the increase of clinical stage, the expression rate of stage Ⅲ was significantly lower than that of stage Ⅰ ~ Ⅱ. Conclusions PTEN and CyclinD1 protein can be used as clinical diagnosis of cervical squamous cell carcinoma, early diagnosis and scientific evaluation of prognosis of the tumor, to guide clinical observation of biological indicators.